65 related articles for article (PubMed ID: 19006068)
1. Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson's disease patients.
Camgrand E; Christine BC; Harroch E; Chouquet C; Barthelemy C; Ory-Magne F; Leung C; Barbosa RP; Rascol O; Fabbri M
Parkinsonism Relat Disord; 2023 Nov; 116():105859. PubMed ID: 37788512
[No Abstract] [Full Text] [Related]
2. Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review.
Kukkle PL; Garg D; Merello M
Mov Disord Clin Pract; 2023 Sep; 10(9):1253-1267. PubMed ID: 37772305
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.
Zagnoli F; Leblanc A; Viakhireva-Dovganyuk I; Delabrousse-Mayoux JP; Pouyet A; Ziegler M; Sogni L; Patat M; Bouillot R; Vérin M;
J Neural Transm (Vienna); 2023 Nov; 130(11):1463-1474. PubMed ID: 36862190
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease.
Hagell P; Höglund A; Hellqvist C; Johansson EL; Löwed B; Sjöström AC; Karlberg C; Lundgren M; Dizdar N; Johansson A; Willows T; Rådberg J; Bergquist F
J Neurol; 2020 Nov; 267(11):3411-3417. PubMed ID: 32613445
[TBL] [Abstract][Full Text] [Related]
5. A Novel Method of Treating Apomorphine-Induced Subcutaneous Nodules.
Novo Ponte S; García Malo C; Blasco Quílez MR; Sánchez Alonso P
Mov Disord Clin Pract; 2020 Jan; 7(1):83-85. PubMed ID: 31970216
[No Abstract] [Full Text] [Related]
6. Old Drugs, New Delivery Systems in Parkinson's Disease.
Gupta HV; Lyons KE; Pahwa R
Drugs Aging; 2019 Sep; 36(9):807-821. PubMed ID: 31161581
[TBL] [Abstract][Full Text] [Related]
7. The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues.
Skorvanek M; Bhatia KP
Mov Disord Clin Pract; 2017; 4(1):21-31. PubMed ID: 30363435
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.
Auffret M; Drapier S; Vérin M
Clin Drug Investig; 2018 Apr; 38(4):287-312. PubMed ID: 29327219
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine nodules in Parkinson's disease: best practice considerations.
Todd A; James CA
Br J Community Nurs; 2008 Oct; 13(10):457-63. PubMed ID: 19057470
[TBL] [Abstract][Full Text] [Related]
10. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study.
Poltawski L; Edwards H; Todd A; Watson T; Lees A; James CA
Mov Disord; 2009 Jan; 24(1):115-8. PubMed ID: 19006068
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications].
Giménez de Béjar V; Carballo-Cordero M
Rev Neurol; 2012; 55 Suppl 1():S25-9. PubMed ID: 23169230
[TBL] [Abstract][Full Text] [Related]
13. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
Pot C; Oppliger R; Castillo V; Coeytaux A; Hauser C; Burkhard PR
Neurology; 2005 Jan; 64(2):392-3. PubMed ID: 15668455
[No Abstract] [Full Text] [Related]
14. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
